Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
Summary
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Calidi), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering.The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. Calidis clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidis preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. For more information, please visit www.calidibio.com.This press release may contain forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained in this discussion are based on Calidis current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements.